Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | June 05, 2026 | June 08, 2026 |
| ZIM Integrated Shipping Services Ltd.ZIM · Entity 4177 | CEO | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 19,296 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 14,492 · Balance 19,296 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Exercise / conversion · Disposed 14,492 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.
ZIM Integrated Shipping Services Ltd.
Report date July 01, 2026 · Filed July 02, 2026
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261712 · ownership.xml · derivative · entry 2 Lichtenstein Chen · CIK 0002046465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F3 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-261712 · ownership.xml · nonDerivative · entry 1 Lichtenstein Chen · CIK 0002046465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 7,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-251405 · ownership.xml · derivative · entry 1 Lichtenstein Chen · CIK 0002046465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,242 Underlying: Ordinary Shares · 7,242 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F2 · derivative.expiration_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 4,804 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-308057 · ownership.xml · derivative · entry 2 Lichtenstein Chen · CIK 0002046465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,804 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on December 2, 2024 and vested on December 2, 2025. F3 · derivative.expiration_date: Restricted share units were granted on December 2, 2024 and vested on December 2, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 4,804 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-308057 · ownership.xml · nonDerivative · entry 1 Lichtenstein Chen · CIK 0002046465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083715 · ownership.xml · derivative · entry 1 Lichtenstein Chen · CIK 0002046465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,492 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F2 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:07 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 4,804 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133246 · ownership.xml · derivative · entry 1 Lichtenstein Chen · CIK 0002046465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,804 Underlying: Ordinary Shares · 4,804 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on December 2, 2024 and vest on December 2, 2025. F2 · derivative.expiration_date: Restricted share units were granted on December 2, 2024 and vest on December 2, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.